Case Type: Mergers & Acquisitions

TWC Tech Holdings II Corp. (TWCT) relating to its proposed merger with Cellebrite DI Ltd. Under the terms of the agreement, TWCT will acquire Cellebrite through a reverse merger, with Cellebrite emerging as a publicly traded company.

Soaring Eagle Acquisition Corp. (SRNG) relating to its proposed merger with Ginkgo Bioworks, Inc. Under the terms of the agreement, SRNG will acquire Ginkgo through a reverse merger, with Ginkgo emerging as a publicly traded company.

Good Works Acquisition Corp. (GWAC) relating to its proposed merger with Cipher Mining Technologies, Inc. Under the terms of the agreement, GWAC will acquire Cipher through a reverse merger, with Cipher emerging as a publicly traded company.

CF Finance Acquisition Corp. III (CFAC) relating to its proposed merger with AEye, Inc. Under the terms of the agreement, CFAC will acquire AEye through a reverse merger, with AEye emerging as a publicly traded company.

People’s Bancorp, Inc. (PEBO) relating to its proposed acquisition of Limestone Bancorp, Inc. Under the terms of the agreement, PEBO shareholders will own approximately 80% of the combined company.

Discovery, Inc. (DISCA) relating to its proposed merger with AT&T Inc. Under the terms of the agreement, Discovery;s entertainment and sports businesses are to combine with WarnerMedia to create a standalone company. Discovery shareholders are expected to own only 29% of the new company.

Ondas Holdings, Inc. (ONDS) relating to its proposed acquisition of American Robotics, Inc. Under the terms of the agreement, ONDS shareholders will receive a mix of cash and equity.

Core-Mark Holding Company, Inc. (CORE) relating to its proposed acquisition by Performance Food Group Co. Under the terms of the agreement, CORE shareholders will receive $23.875 in cash and 0.44 shares of PFG per share they own.

Altabancorp (ALTA) relating to its proposed merger with Glacier Bancorp, Inc. Under the terms of the agreement, ALTA shareholders will receive 0.7971 shares of Glacier per share they own.

Aerpio Pharmaceuticals, Inc. (ARPO) relating to its proposed merger with Aadi Bioscience, Inc. Under the terms of the agreement, ARPO shareholders are expected to own 14.7% of the combined company after the closing of the concurrent PIPE financing transaction.